Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

@article{Mateos2013LenalidomidePD,
  title={Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.},
  author={Mar{\'i}a Victoria Mateos and M A Tejero Hern{\'a}ndez and Pilar Giraldo and Javier de la Rubia and Felipe de Arriba and Luc{\'i}a L{\'o}pez Corral and Laura Rosi{\~n}ol and Bruno Paiva and Luis Palomera and Joan Bargay and Albert Oriol and Felipe Pr{\'o}sper and Javier L{\'o}pez and Eduardo Olavarr{\'i}a and Nuria E Quintana and Jose-luis Garc{\'i}a and Joan Blad{\'e} and J J Lahuerta and Jes{\'u}s-F San Miguel},
  journal={The New England journal of medicine},
  year={2013},
  volume={369 5},
  pages={438-47}
}
BACKGROUND For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early intervention. METHODS In this randomized, open-label, phase 3 trial, we randomly assigned 119 patients with high-risk smoldering myeloma to treatment or observation. Patients in the treatment group received an induction regimen (lenalidomide at a dose of 25 mg per day on days 1 to 21, plus… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 116 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma

  • J Hillengass, K Fechtner, MA Weber
  • J Clin Oncol 2010;28:1606-10
  • 2010

Similar Papers

Loading similar papers…